HUTCHMED (NASDAQ:HCM) versus Celldex Therapeutics (NASDAQ:CLDX) Financial Survey

HUTCHMED (NASDAQ:HCM) and Celldex Therapeutics (NASDAQ:CLDX) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.

Profitability

This table compares HUTCHMED and Celldex Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
HUTCHMED	N/A	N/A	N/A
Celldex Therapeutics	-3,446.88%	-41.67%	-38.86%

Analyst Ratings

This is a breakdown of current recommendations for HUTCHMED and Celldex Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	1	3	1	1	2.33
Celldex Therapeutics	2	1	7	1	2.64

HUTCHMED currently has a consensus target price of $20.88, indicating a potential upside of 45.67%. Celldex Therapeutics has a consensus target price of $44.20, indicating a potential upside of 46.89%. Given Celldex Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Celldex Therapeutics is more favorable than HUTCHMED.

Valuation and Earnings

This table compares HUTCHMED and Celldex Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	$630.20 million	3.97	$37.73 million	N/A	N/A
Celldex Therapeutics	$1.54 million	1,300.71	-$258.76 million	($3.89)	-7.74

HUTCHMED has higher revenue and earnings than Celldex Therapeutics.

Insider and Institutional Ownership

8.8% of HUTCHMED shares are held by institutional investors. 3.6% of HUTCHMED shares are held by insiders. Comparatively, 4.4% of Celldex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

HUTCHMED has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

About Celldex Therapeutics

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company’s clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.